Summit Able To Promote Apex Plus For LASIK At Ophthalmology Conference
This article was originally published in The Gray Sheet
Summit Technology's receipt on Oct. 21 of FDA approval for its Apex Plus excimer laser for use in laser-assisted in-situ keratomileusis (LASIK) could help the firm increase its market share by 30%, the firm says. Analysts estimate the firm's stake at 20%.
You may also be interested in...
A July 22 recommendation that Visx' Star S2 excimer laser be approved for in situ keratomileusis (LASIK) procedures was precipitated by a consensus desire on the part of FDA's Ophthalmic Devices Panel to disseminate study data through product labeling.
No device-related warning letters were released by the US FDA the week of 26 January.
Karyopharm and GSK should soon learn whether the European Medicines Agency will recommend EU approval for their respective products, selinexor and dostarlimab.